13 February 2018 - - Deerfield, Illinois-based marketing and sales organization Takeda Pharmaceuticals, USA, Inc. has published a study utilizing a novel simulation model to predict treatment response in patients with moderately to severely active ulcerative colitis and help better understand optimal treatment positioning, the company said.
The study, titled "Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model," was published on January 18, 2018 in Inflammatory Bowel Diseases.
There are currently limited data comparing treatment algorithms incorporating sequential therapies. For this study researchers employed state-of-the-art simulation modeling to compare multiple treatment scenarios using the evidence currently available.
Scenarios evaluated included the use of Entyvio (vedolizumab) as a first-line biologic therapy for a steroid-dependent patient with moderately to severely active UC.
The model compared four treatment scenarios over the course of one year, incorporating Entyvio in different positions within a typical step-up therapy treatment paradigm for patients dependent on steroids.
Primary analyses included simulating 100 trials of 100,000 patients with outcomes assessed in terms of quality-adjusted life years.
The authors concluded that the results of the model simulation support the use of Entyvio as an initial steroid-sparing biologic therapy in steroid-dependent patients with UC. Clinical trials are needed to directly compare sequential treatment algorithms.
Vedolizumab, a humanized monoclonal antibody available in the US under the trade name Entyvio, is approved in the US simultaneously for the treatment of adults with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha antagonist.
Takeda Pharmaceuticals USA, the US marketing and sales organization of Takeda Pharmaceutical Company Ltd., is driven to improving the lives of patients with GI diseases through innovative medicines, dedicated patient disease management support, and the evolution of the healthcare environment.
The company utilizes a broad approach to treating many diseases that impact the GI system.